<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>N-<z:chebi fb="9" ids="46887">Acetyl</z:chebi>-<z:chebi fb="0" ids="29995">aspartate</z:chebi> (<z:chebi fb="8" ids="32918">NAA</z:chebi>) is almost exclusively localized in neurons in the mature brain and might be used as a neuronal marker </plain></SENT>
<SENT sid="1" pm="."><plain>It has been reported that the <z:chebi fb="8" ids="32918">NAA</z:chebi> content in human brain is decreased in <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> and in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Since the <z:chebi fb="8" ids="32918">NAA</z:chebi> content can be determined by nuclear magnetic resonance techniques, it has potential as a diagnostic and prognostic marker </plain></SENT>
<SENT sid="3" pm="."><plain>The objective of this study was to examine the change of <z:chebi fb="8" ids="32918">NAA</z:chebi> content and related substances following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and compare the results to the damage of the tissue </plain></SENT>
<SENT sid="4" pm="."><plain>We used rats to study the changes of <z:chebi fb="8" ids="32918">NAA</z:chebi>, N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-aspartyl-<z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> (NAAG), <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>, and <z:chebi fb="0" ids="29995">aspartate</z:chebi> contents over a time course of 24 h in brain regions affected by either permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) or decapitation (global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>The decreases of <z:chebi fb="8" ids="32918">NAA</z:chebi> and NAAG contents following global <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> were linear over time but significant only after 4 and 2 h, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>After 24 h, the levels of <z:chebi fb="8" ids="32918">NAA</z:chebi> and NAAG were 24 and 44% of control values, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The concentration of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> did not change, whereas the <z:chebi fb="0" ids="29995">aspartate</z:chebi> content increased at a rate comparable with the rate of decrease of <z:chebi fb="8" ids="32918">NAA</z:chebi> content </plain></SENT>
<SENT sid="8" pm="."><plain>This is consistent with <z:chebi fb="8" ids="32918">NAA</z:chebi> being preferentially degraded by the enzyme amidohydrolase II in global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, there was a rapid decline of <z:chebi fb="8" ids="32918">NAA</z:chebi> within the first 8 h of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> followed by a slower rate of reduction </plain></SENT>
<SENT sid="10" pm="."><plain>The reductions of <z:chebi fb="8" ids="32918">NAA</z:chebi> and NAAG contents in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> were significant after 4 and 24 h, respectively.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>